Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 103

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 103
---
 —

    —

    Outstanding June
    30, 2024

    82,045

    $
    61.59

    9.63

    Exercisable June
    30, 2024

    11,662

    $
    226.80

    8.61

A
summary of the status of the Company’s nonvested options as of June 30, 2025 and 2024, and changes during the three and
six months ended June 30, 2025 and 2024, is presented below:

    Non-vested
    Options
     
    Options

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2024

    56,093

    $
    29.30

    Granted

    7,899

    13.50

    Vested

    (19,957
    ) 

    4.85

    Forfeited

    —

    —

    Non-vested at June 30, 2025

    44,035

    $
    47.85

    18 

    Non-vested
    Options
     
    Options

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    11,344

    $
    226.80

    Granted

    63,400

    $
    13.00

    Vested

    (4,360
    )
     
    $
    226.80

    Forfeited

    —

    $
    —

    Non-vested at
    June 30, 2024

    70,384

    $
    34.20

The
Company recognized stock-based compensation expense related to option vesting amortization of $341,576 and $366,503 for
three months ended June 30, 2025 and 2024, respectively, which is included in general and administrative expenses in the condensed
consolidated statements of operations. The Company recognized stock-based compensation expense related to option vesting amortization
of $745,497 and $659,055 for six months ended June 30, 2025 and 2024, respectively, which is included in general and
administrative expenses